Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

January 28, 2025 08:30 ET | Source: Eterna Therapeutics

Eterna Therapeutics Announces Expansion of Scientific Advisory Board

CAMBRIDGE, Mass., Jan. 28, 2025 (GLOBE NEWSWIRE) -- Eterna Therapeutics (Nasdaq: ERNA), a leader in cell therapies for the treatment of advanced solid tumors, today announced the addition of Jerome...
January 09, 2025 07:30 ET | Source: Eterna Therapeutics

Eterna Therapeutics Announces Appointment of Dr. Elena Ratner to Board of Directors

CAMBRIDGE, Mass., Jan. 09, 2025 (GLOBE NEWSWIRE) -- Eterna Therapeutics (Nasdaq: ERNA), a leader in cell therapies for the treatment of advanced solid tumors, today announced the appointment of...
December 03, 2024 08:30 ET | Source: Eterna Therapeutics

Eterna Therapeutics Launches Research to Evaluate its Lead Induced Mesenchymal Stem Cell Therapy Candidate’s (ERNA-101) Ability to Induce and Modulate Antitumor Immunity in Ovarian Cancer and Breast Cancer Models

Eterna Launches Research to Evaluate its Lead iMSC Therapy Candidate’s Ability to Induce and Modulate Antitumor Immunity in Ovarian and Breast Models
November 25, 2024 08:30 ET | Source: Eterna Therapeutics

Eterna Therapeutics Announces Up to $1 Million Stock Repurchase Program

Eterna Therapeutics Announces $1 Million Stock Repurchase Program
October 30, 2024 08:30 ET | Source: Eterna Therapeutics

Eterna Therapeutics Completes Strategic Financial Restructuring with the Aim to Accelerate its Developmental Activities and Long-Term Success

Eterna Therapeutics Completes Strategic Financial Restructuring with the Aim to Accelerate its Developmental Activities and Long-Term Success
October 17, 2024 08:00 ET | Source: Eterna Therapeutics

Eterna Therapeutics and Factor Bioscience Announce Exclusive License and Collaboration Agreement to Accelerate Cell Therapy Development for Oncology, Autoimmune, and Rare Diseases

CAMBRIDGE, Mass., Oct. 17, 2024 (GLOBE NEWSWIRE) -- Eterna Therapeutics Inc. (Nasdaq: ERNA) (“Eterna” or the “Company”) and Factor Bioscience Limited (“Factor”) today announced an exclusive license...